Castle Biosciences Inc
NASDAQ:CSTL
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
17.4
34.67
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Castle Biosciences Inc
Castle Biosciences Inc
Current Portion of Long-Term Debt
Castle Biosciences Inc
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Castle Biosciences Inc
NASDAQ:CSTL
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
DaVita Inc
NYSE:DVA
|
Current Portion of Long-Term Debt
$296.3m
|
CAGR 3-Years
21%
|
CAGR 5-Years
20%
|
CAGR 10-Years
9%
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Current Portion of Long-Term Debt
$603m
|
CAGR 3-Years
745%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
39%
|
|
|
CVS Health Corp
NYSE:CVS
|
Current Portion of Long-Term Debt
$4.9B
|
CAGR 3-Years
47%
|
CAGR 5-Years
5%
|
CAGR 10-Years
24%
|
|
|
Cigna Corp
NYSE:CI
|
Current Portion of Long-Term Debt
$937m
|
CAGR 3-Years
244%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
23%
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Current Portion of Long-Term Debt
$1.4B
|
CAGR 3-Years
387%
|
CAGR 5-Years
23%
|
CAGR 10-Years
31%
|
|
Castle Biosciences Inc
Glance View
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company is headquartered in Friendswood, Texas and currently employs 342 full-time employees. The company went IPO on 2019-07-25. The company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. The firm markets five multi-analyte assays with algorithmic analysis (MAAA) tests for use in the dermatologic, ocular and gastroenterology fields: DecisionDx-Melanoma, DecisionDx-SCC, Comprehensive Diagnostic Offering (CDO), DecisionDx-UM and TissueCypher Barrett’s Esophagus Assay. DecisionDx-Melanoma is risk stratification gene expression profile (GEP) test developed to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. DecisionDx-SCC, a 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma (SCC) metastasis for patients with one or more risk factors.
You don't have any saved screeners yet
